Management ChangeMay 14, 2026, 08:17 AM
Corbus Pharma Appoints Brent Pfeiffenberger to Board; Expands Equity Plan
AI Summary
Corbus Pharmaceuticals Holdings, Inc. appointed Brent Pfeiffenberger, a seasoned pharma industry veteran, to its Board of Directors, expanding the board to seven members. Dr. Pfeiffenberger brings extensive experience from leadership roles at Century Therapeutics, Neogene Therapeutics, and Bristol-Myers Squibb, particularly in oncology. Concurrently, stockholders approved an amendment to the 2024 Equity Compensation Plan, increasing the authorized shares for issuance by 3,000,000 to a total of 5,000,000 shares. The company anticipates important data readouts for its CRB-701 and CRB-913 clinical programs this summer, alongside the expected initiation of a registrational study for CRB-701.
Key Highlights
- Brent Pfeiffenberger, age 48, was appointed to Corbus Pharmaceuticals' Board of Directors, expanding the board to seven members.
- Dr. Pfeiffenberger currently serves as President and CEO and Chairman of Century Therapeutics, Inc.
- He previously held leadership roles at Neogene Therapeutics Inc. and Bristol-Myers Squibb Company, including SVP and Head of U.S. Oncology.
- Dr. Pfeiffenberger will receive an annual cash retainer of $40,000 and annual equity awards.
- Stockholders approved an amendment to the 2024 Equity Compensation Plan, increasing authorized shares by 3,000,000 to 5,000,000.
- Corbus expects important data readouts for CRB-701 and CRB-913 clinical programs this summer.
Price Impact
More from CRBP